الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 134 |  |  |
| | | from | 134 | | |
Abstract
Cancer is among the leading causes of death worldwide. Currently, there is a growing interest in combining anticancer drugs to maximize efficacy and minimize side effects. The current study was designed to evaluate the possible anticancer effect of chloroquine (autophagy inhibitor drug), gemifloxacin (Topo II inhibitor drug) and their combination with doxorubicin. MCF7 and A549 cancer cell lines were treated with doxorubicin and doxorubicin combinations to measure IC50. The In-vitro antioxidant activity was also measured. In the in-vivo experiment, mice were divided into seven groups: group 1 normal control group, group 2 positive control, group 3 injected with doxorubicin (2 mg/kg) i.v., group 4 given chloroquine (25 mg/kg) P.O, group 5 received gemifloxacin (25 mg/kg) P.O, group 6 treated with a combination of doxorubicin and chloroquine and group7 treated with a combination of doxorubicin and gemifloxacin. Blood biochemical parameters and histopathological picture were studied. Results showed that doxorubicin combinations showed higher cytotoxic effect on MCF7 and A549 cell lines than doxorubicin alone. Furthermore, these combinations improved hematological parameters and histopathological pictures in the treated mice.